NO20004217L - Inhibitors of phospholipase A2 - Google Patents
Inhibitors of phospholipase A2Info
- Publication number
- NO20004217L NO20004217L NO20004217A NO20004217A NO20004217L NO 20004217 L NO20004217 L NO 20004217L NO 20004217 A NO20004217 A NO 20004217A NO 20004217 A NO20004217 A NO 20004217A NO 20004217 L NO20004217 L NO 20004217L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- phospholipase
- iii
- group
- chemical form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Det er beskrevet inhibitorer av cPLA2 aktivitet, som har en kjemisk forme), valgt fra gruppen omfattende og (I), (II), og (III), (IV), (V) eller (VI).Inhibitors of cPLA2 activity, which have a chemical form), are selected from the group comprising and (I), (II), and (III), (IV), (V) or (VI).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3010298A | 1998-02-25 | 1998-02-25 | |
PCT/US1999/003388 WO1999043672A1 (en) | 1998-02-25 | 1999-02-17 | Inhibitors of phospholipase a2 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20004217D0 NO20004217D0 (en) | 2000-08-23 |
NO20004217L true NO20004217L (en) | 2000-10-23 |
Family
ID=21852517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20004217A NO20004217L (en) | 1998-02-25 | 2000-08-23 | Inhibitors of phospholipase A2 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1062216A1 (en) |
JP (1) | JP2002504551A (en) |
KR (1) | KR20010041346A (en) |
CN (1) | CN1298404A (en) |
AU (1) | AU3297099A (en) |
BG (1) | BG104781A (en) |
BR (1) | BR9909242A (en) |
CA (1) | CA2322163A1 (en) |
EA (1) | EA200000873A1 (en) |
EE (1) | EE200000522A (en) |
HR (1) | HRP20000513A2 (en) |
HU (1) | HUP0100156A3 (en) |
ID (1) | ID26123A (en) |
IL (1) | IL137540A0 (en) |
NO (1) | NO20004217L (en) |
PL (1) | PL342516A1 (en) |
SK (1) | SK12782000A3 (en) |
TR (1) | TR200002445T2 (en) |
WO (1) | WO1999043672A1 (en) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053275A2 (en) * | 2000-01-17 | 2001-07-26 | Bayer Aktiengesellschaft | Substituted aryl ketones |
AU2001271531A1 (en) * | 2000-06-27 | 2002-01-08 | Smith Kline Beecham Corporation | Fatty acid synthase inhibitors |
WO2002005796A2 (en) * | 2000-07-14 | 2002-01-24 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
ATE362468T1 (en) | 2000-07-25 | 2007-06-15 | Merck & Co Inc | N-SUBSTITUTED INDOLES WITH APPLICATION IN THE TREATMENT OF DIABETES |
ATE524441T1 (en) | 2000-12-28 | 2011-09-15 | Daiichi Seiyaku Co | VLA-4 INHIBITORS |
WO2002094830A2 (en) * | 2001-05-23 | 2002-11-28 | Merck Frosst Canada & Co. | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
US7291639B2 (en) | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
JP4399253B2 (en) | 2001-06-20 | 2010-01-13 | ワイス | Substituted indoleic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
PL370342A1 (en) | 2001-09-27 | 2005-05-16 | F.Hoffmann-La Roche Ag | Indole derivatives as cox ii inhibitors |
US6984735B2 (en) | 2001-12-03 | 2006-01-10 | Wyeth | Process for making an aldehyde |
US7713964B2 (en) | 2001-12-03 | 2010-05-11 | Wyeth Llc | Methods for treating asthmatic conditions |
US6635771B2 (en) | 2001-12-03 | 2003-10-21 | Wyeth | N-benzhydryl indole compounds |
US7101875B2 (en) | 2001-12-03 | 2006-09-05 | Wyeth | Methods for treating arthritic disorders |
US6797708B2 (en) | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
US7605156B2 (en) | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
US7247741B2 (en) * | 2005-01-21 | 2007-07-24 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
EA200500289A1 (en) | 2002-07-31 | 2005-06-30 | Еуро-Селтик С. А. | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCATORS |
US7393960B2 (en) | 2002-08-29 | 2008-07-01 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
ES2342596T3 (en) | 2002-08-29 | 2010-07-09 | MERCK SHARP & DOHME CORP. | INDOLES WITH ANTI-DIABETIC ACTIVITY. |
US7795280B2 (en) | 2002-11-07 | 2010-09-14 | N.V. Organon | Indoles useful in the treatment of androgen-receptor related diseases |
UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
US7056943B2 (en) | 2002-12-10 | 2006-06-06 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
ATE331709T1 (en) | 2002-12-10 | 2006-07-15 | Wyeth Corp | SUBSTITUTED 3-CARBONYL-1-YL ACETIC ACID DERIVATIVES AS PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) INHIBITORS |
DE60306547T2 (en) | 2002-12-10 | 2007-06-28 | Wyeth | SUBSTITUTED 3-ALKYL AND 3-ARYL ALKYL-1H-INDOL-1-YL-ACETIC ACID DERIVATIVES AS PLASMINOGEN ACTIVATOR |
EP1569901B1 (en) | 2002-12-10 | 2008-10-15 | Wyeth | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) |
US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
US7094790B2 (en) | 2003-05-07 | 2006-08-22 | Abbott Laboratories | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
ES2465624T3 (en) * | 2003-07-11 | 2014-06-06 | Merck Patent Gmbh | Benzimidazole carboxamides as inhibitors of RAF kinase |
ES2382806T3 (en) | 2003-07-24 | 2012-06-13 | Daiichi Sankyo Company, Limited | Cyclohexanecarboxylic acid compound |
BRPI0413072A (en) * | 2003-07-28 | 2006-10-03 | Janssen Pharmaceutica Nv | lta4h modulators |
US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
TW200602317A (en) | 2004-04-23 | 2006-01-16 | Akzo Nobel Nv | Novel androgens |
US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
CA2570363A1 (en) | 2004-06-18 | 2005-12-29 | Biolipox Ab | Indoles useful in the treatment of inflammation |
US7754747B2 (en) | 2004-08-23 | 2010-07-13 | Wyeth Llc | Oxazolo-naphthyl acids |
WO2006034418A2 (en) * | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
SI1809602T1 (en) | 2004-10-27 | 2009-04-30 | Janssen Pharmaceutica Nv | Indole derivatives useful as progesterone receptor modulators |
WO2006045478A1 (en) * | 2004-10-27 | 2006-05-04 | F. Hoffmann-La Roche Ag | New indole or benzimidazole derivatives |
JP2008527027A (en) * | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | Indoles useful for the treatment of inflammation |
US8097623B2 (en) | 2005-01-19 | 2012-01-17 | Biolipox Ab | Indoles useful in the treatment of inflammation |
JP2008527030A (en) * | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | Indoles useful for the treatment of inflammation |
WO2006077365A1 (en) * | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
WO2006109633A1 (en) * | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | Substituted indole compound |
TW200718687A (en) | 2005-05-27 | 2007-05-16 | Wyeth Corp | Inhibitors of cytosolic phospholipase A2 |
AU2006279496A1 (en) | 2005-08-17 | 2007-02-22 | Wyeth | Substituted indoles and use thereof |
AR056690A1 (en) | 2005-10-14 | 2007-10-17 | Athersys Inc | INDOL DERIVATIVES AS INDOL INHIBITORS AS INHIBITORS OF HISTAMINE RECEIVER 3 FOR THE PARKING OF SUENO DISORDERS AND COGNITIVES OBESITY AND OTHER SNC DISORDERS |
EP1779848A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
MX2008005666A (en) | 2005-11-03 | 2009-03-02 | Ilypsa Inc | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors. |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
WO2008009924A2 (en) * | 2006-07-18 | 2008-01-24 | Biolipox Ab | Indoles useful in the treatment of inflammation |
EA018724B1 (en) | 2006-08-07 | 2013-10-30 | Айронвуд Фармасьютикалз, Инк. | Indole compounds |
CA2712854C (en) | 2008-01-31 | 2016-02-23 | Sanofi-Aventis | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals |
JP5791500B2 (en) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ,エルエルシー. | 5-lipoxygenase activating protein inhibitor |
MX2011003239A (en) | 2008-09-26 | 2011-04-28 | Merck Sharp & Dohme | Novel cyclic benzimidazole derivatives useful anti-diabetic agents. |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051176A1 (en) | 2008-10-29 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5677425B2 (en) | 2009-06-29 | 2015-02-25 | インサイト・コーポレイションIncyte Corporation | Pyrimidinone as a PI3K inhibitor |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
SG182662A1 (en) | 2010-01-28 | 2012-08-30 | Harvard College | Compositions and methods for enhancing proteasome activity |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
BR112012024380A2 (en) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | chemical compounds |
CA2796311A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | Fused derivatives as pi3k.delta. inhibitors |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
EP2600864B1 (en) * | 2010-08-04 | 2019-01-09 | University Of Virginia Patent Foundation | Compositions and methods for treating inflammatory diseases |
CN103201262B (en) | 2010-08-20 | 2016-06-01 | 艾米拉医药股份有限公司 | Autotaxin inhibitors and application thereof |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
AR084433A1 (en) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
WO2012154967A1 (en) | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
KR102507287B1 (en) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Heterocyclylamines as pi3k inhibitors |
ES2790358T3 (en) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation |
PT2797416T (en) | 2011-12-28 | 2017-10-23 | Global Blood Therapeutics Inc | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
JP2015526520A (en) | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Benzimidazole derivatives as ITK inhibitors |
WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
MY180206A (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN105073728A (en) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
JP2016531874A (en) | 2013-09-26 | 2016-10-13 | ファーマケア,インク. | Autotaxin inhibitor compounds |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
WO2015074064A2 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
EA201992707A1 (en) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
EP3071205B1 (en) | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazine compositions as bet bromodomain inhibitors |
DK3102208T3 (en) | 2014-02-07 | 2021-03-08 | Global Blood Therapeutics Inc | CRYSTALLINIC POLYMORPH OF THE FREE BASE OF 2-HYDROXY-6 - ((2- (1-ISOPROPYL-1H-PYRAZOL-5-YL) PYRIDIN-3-YL) METHOXY) BENZALDEHYDE |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
PE20180129A1 (en) | 2015-02-27 | 2018-01-18 | Incyte Corp | PI3K INHIBITOR SALTS AND PREPARATION PROCESSES |
MA41841A (en) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
MA43373A (en) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | DOSAGE REGIMES FOR 2-HYDROXY-6 - ((2- (1-ISOPROPYL-1H-PYRAZOL-5-YL) PYRIDIN-3-YL) METHOXY) BENZALDEHYDE |
EP3390396B1 (en) | 2015-12-15 | 2022-07-06 | Astrazeneca AB | Isoindole compounds |
AR108435A1 (en) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | PROCESS TO SYNTHETIZE 2-HYDROXI-6 - ((2- (1-ISOPROPIL-1H-PIRAZOL-5-IL) -PIRIDIN-3-IL) METOXI) BENZALDEHYDE |
TWI778983B (en) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
DK3860998T3 (en) | 2018-10-05 | 2024-03-25 | Annapurna Bio Inc | Compounds and compositions for treating conditions associated with APJ receptor activity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
DE4338770A1 (en) * | 1993-11-12 | 1995-05-18 | Matthias Dr Lehr | Indole-2-alkanoic acids and their derivatives as inhibitors of phospholipase A¶2¶ |
PT848004E (en) * | 1995-07-31 | 2003-07-31 | Shionogi & Co | PIRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITING ACTIVITY |
JP2000515529A (en) * | 1996-08-01 | 2000-11-21 | メルクル・ゲーエムベーハー | Acylpyrrolidone dicarboxylic acid, acyl indole dicarboxylic acid and derivatives thereof as inhibitors of cytoplasmic phospholipase A |
JP2000516958A (en) * | 1996-08-26 | 2000-12-19 | ジェネティックス・インスチチュート・インコーポレーテッド | Phospholipase enzyme inhibitors |
-
1999
- 1999-02-17 CA CA002322163A patent/CA2322163A1/en not_active Abandoned
- 1999-02-17 EP EP99936073A patent/EP1062216A1/en not_active Withdrawn
- 1999-02-17 AU AU32970/99A patent/AU3297099A/en not_active Abandoned
- 1999-02-17 CN CN99805379A patent/CN1298404A/en active Pending
- 1999-02-17 ID IDW20001568A patent/ID26123A/en unknown
- 1999-02-17 EA EA200000873A patent/EA200000873A1/en unknown
- 1999-02-17 IL IL13754099A patent/IL137540A0/en unknown
- 1999-02-17 WO PCT/US1999/003388 patent/WO1999043672A1/en not_active Application Discontinuation
- 1999-02-17 PL PL99342516A patent/PL342516A1/en unknown
- 1999-02-17 SK SK1278-2000A patent/SK12782000A3/en unknown
- 1999-02-17 EE EEP200000522A patent/EE200000522A/en unknown
- 1999-02-17 KR KR1020007009459A patent/KR20010041346A/en not_active Application Discontinuation
- 1999-02-17 TR TR2000/02445T patent/TR200002445T2/en unknown
- 1999-02-17 JP JP2000533428A patent/JP2002504551A/en not_active Withdrawn
- 1999-02-17 BR BR9909242-5A patent/BR9909242A/en not_active IP Right Cessation
- 1999-02-17 HU HU0100156A patent/HUP0100156A3/en unknown
-
2000
- 2000-07-31 HR HR20000513A patent/HRP20000513A2/en not_active Application Discontinuation
- 2000-08-23 NO NO20004217A patent/NO20004217L/en not_active Application Discontinuation
- 2000-09-19 BG BG104781A patent/BG104781A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1999043672A1 (en) | 1999-09-02 |
CN1298404A (en) | 2001-06-06 |
EE200000522A (en) | 2002-02-15 |
KR20010041346A (en) | 2001-05-15 |
AU3297099A (en) | 1999-09-15 |
ID26123A (en) | 2000-11-23 |
HUP0100156A3 (en) | 2002-12-28 |
NO20004217D0 (en) | 2000-08-23 |
TR200002445T2 (en) | 2000-12-21 |
BG104781A (en) | 2001-10-31 |
IL137540A0 (en) | 2001-07-24 |
BR9909242A (en) | 2000-11-14 |
HRP20000513A2 (en) | 2001-12-31 |
EP1062216A1 (en) | 2000-12-27 |
WO1999043672A9 (en) | 2000-05-04 |
SK12782000A3 (en) | 2001-04-09 |
HUP0100156A2 (en) | 2001-07-30 |
EA200000873A1 (en) | 2001-04-23 |
JP2002504551A (en) | 2002-02-12 |
PL342516A1 (en) | 2001-06-18 |
CA2322163A1 (en) | 1999-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20004217L (en) | Inhibitors of phospholipase A2 | |
NO20005224D0 (en) | BTK inhibitors and methods for their identification and use | |
DK1114032T3 (en) | 4-Amino-substituted-2-substituted-1,2,3,4-tetrahydroquinolines as CETB inhibitors | |
DZ3004A1 (en) | Omega-carboxyaryl diphenyl substituted ureas as raf kinase inhibitors. | |
BR0016735A (en) | Method for more effective data transmission, and data transmission protocol | |
NO20023981L (en) | Antiviral azaindole derivatives | |
ATE268750T1 (en) | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | |
WO1999043651A3 (en) | Inhibitors of phospholipase enzymes | |
DK1091928T3 (en) | Novel acylated pseudodipeptides, processes for their preparation and compositions containing them | |
DK0984665T3 (en) | Transducer for partially or completely implantable hearing aid | |
DE69715038D1 (en) | FUNGICIDE COMPOSITIONS BASED ON (N-PHENYLACETYL-N-2,6-XYLYL) METHYLALANINATE | |
WO2003003004A3 (en) | Method for identifying compounds the specifically deplete mast cells | |
WO2000053583A8 (en) | Inhibitors of protein tyrosine phosphatase | |
BR0307886B1 (en) | Refractory product containing more than 85% zirconia (zro2). | |
NO20045562L (en) | Sulfur-containing phospholipid derivatives | |
TR200002903T2 (en) | Phosphorus containing leaf herbicides, based on synergistic herbicides | |
NO975975L (en) | Vitronectin receptor antagonists, preparation and use thereof | |
DK1141358T3 (en) | Stably transfected cells to identify compounds affecting the stability of mRNA | |
DK1082373T3 (en) | Adhesive System | |
NO20013142L (en) | Substituted (aminoiminomethyl or aminomethyl) benzoheteroarl compounds | |
NO20060065L (en) | Tablets containing enrofloxacin and flavoring and / or flavoring agents | |
TR200101746T2 (en) | Pharmaceutical formulations. | |
NZ320259A (en) | Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors | |
NO20002588L (en) | Bifenylamidinderivater | |
NO995438D0 (en) | Methods for screening compounds useful for preventing infection or pathogenicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |